7-Desmethoxy-7-fluoro Elvitegravir(CAS: 869893-92-5)

The production, import, and use of 7-Desmethoxy-7-fluoro Elvitegravir (CAS: 869893-92-5) are governed by the REACH regulations in the European Union. In the USA, it is regulated by the FDA and EPA. It is also subject to GHS classification for hazardous substance handling. Special attention should be given to its potential for aquatic toxicity and mutagenicity during disposal.

In the synthesis of antiretroviral drugs like Elvitegravir, alternative reagents such as fluoroalkyl sulfonates or fluoroalkyl phosphates can be used as substitutes. However, the choice of alternative reagents depends on the specific reaction conditions and the desired product purity.

The market for 7-Desmethoxy-7-fluoro Elvitegravir (CAS: 869893-92-5) is closely tied to its application in antiretroviral therapy, particularly in combination with other HIV medications. Research trends include efforts to improve drug delivery systems and to explore its potential in treating other diseases. Market dynamics suggest increasing demand in developing countries, driven by rising health awareness and improved healthcare infrastructure.

Waste containing 7-Desmethoxy-7-fluoro Elvitegravir (CAS: 869893-92-5) should be collected and disposed of in accordance with local and international waste management regulations. Incineration is a common method, but professional waste disposal services are recommended. Environmental protection measures include minimizing the release of the compound into the environment and ensuring that all waste is treated to prevent contamination of soil and water sources.